FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Source: Food and Drug Administration - Category: American Health Source Type: news